NLRP3 and Parkinson disease: p38 inhibitors such as SB203580 and NLRP3 inhibitors like MCC950 not only prevent neurodegeneration in vivo but also alleviate motor deficits in the α-Syn-A53T transgenic mouse model of PD [379].